(4) Policy Briefing: A New Agenda For CMS, The Biden White House, And A Democratic Congress The Certara Market Access Channel podcast

A tartalmat a Certara Evidence & Access and Certara Evidence biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a Certara Evidence & Access and Certara Evidence vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.

The Certara Market Access Channel »
(4) Policy Briefing: A new agenda for CMS, the Biden White House, and a Democratic Congress

3+ y ago 20:34

Megosztás

MP3•Epizód kép

We're finally back with a new season for the Radar Podcast, pharma's flagship intelligence briefing on all things market access, real-world evidence, and payer strategy. This program is brought to you by the experts in Certara's global Evidence & Access practice.

In this episode, we're discussing the Biden administration's policy positions, the fate of Trump-era CMS proposals, and what the new majority in the 117th Congress will mean for the biopharma industry.

Your host for this week is Max Goldstein, Director of Business Development, speaking to Ulrich Neumann, Senior Director, Access and Commercial Strategy. For any questions on the topics discussed today, please contact ulrich.neumann@certara.com or download our latest whitepapers here: https://www.certara.com/evidence-access/us-managed-markets/key-trends-us-specialty/

--- Send in a voice message: https://podcasters.spotify.com/pod/show/market-access/message

4 epizódok

#Science #Certara Evidence & Access #Certara Evidence